Across TCGA pan-cancer cohorts, PRTN3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRTN3 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher PRTN3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRTN3 expression acts as an unfavorable survival marker.

SARC and ESCA are the cancer types where PRTN3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.038	0.611	<.001	12	view →
ESCA	OS	Median	All	0.080	0.701	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PRTN3 tumor-vs-normal RNA expression · all PRTN3 data types